After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Dr. Gregory Mattingly, a physician and president of the Midwest Research Group who was involved in Spravato’s original clinical trials, said, “For the first time ... having a space set aside.

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant ... After someone receives the spray, they are left alone to relax in a quiet and ...

In pharma, you've heard us talk about our nasal bi-dose system for Johnson & Johnson's Spravato medication to treat treatment ... will further strengthen our leadership in the respiratory space. And ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

“It was the first time I understood the expression ‘happy place.’ It was this space where everything ... the FDA-approved nasal spray esketamine (Spravato). Because the FDA hasn't approved ...

Photonics researchers from Tampere University, Finland, and Kastler-Brossel Laboratory, France, have demonstrated how ...

Understanding how we conceptualize time out of the complex present moment opens up possibilities for greater causal impact.

The study highlights the existence of a functional hierarchy in the human cerebral cortex, where posterior areas—those that first receive visual information—process space and time together.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...